Use of prion conversion modulating agents
US7598046B2 · kind B2 · utility
0Cited by
8References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 18, 2004 |
| Grant date | Oct 6, 2009 |
| Priority date | — |
| Expiry date | Feb 7, 2025 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/4709
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The use of Apolipoprotein B, Apolipoprotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications In prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in the pathogenesis of transmissible spongiform encephalopathics and other prion diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.